Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Christopher M. Longshaw, PhD
Senior Director, Scientific Affairs EU
Shionogi B.V., United Kingdom
Poster(s):
(P-650)
In vitro
Activity of Cefiderocol and Comparator Agents Against Global Enterobacterales Isolates From Hospitalized Patients with Pneumonia Collected as Part of the SENTRY Surveillance Program (2020-2022)
Thursday, October 17, 2024
12:15 PM – 1:30 PM
US PT
(P-1099) Correlation Analysis of Cefiderocol
In vitro
Activity and
In vivo
Efficacy Against
Acinetobacter baumannii
Strains with Difficult-to-Read MIC Endpoints
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1100) Activity of Cefiderocol and Comparator Agents Against Global Isolates of
Stenotrophomonas maltophilia
from the SENTRY Antimicrobial Surveillance Program (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1472) Cefiderocol Remains Highly Active Against Carbapenemase-Producing Enterobacterales
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1475) Real-World Effectiveness and Safety of Cefiderocol in the Treatment of Patients with Serious Gram-negative Bacterial Infections: Results of the PROVE Chart Review Study
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1484)
In vitro
Activity of Cefiderocol and Comparator Agents Against Non-fermentative Gram-negative Bacilli Isolated from Patients Hospitalized with Pneumonia as part of the SENTRY Global Surveillance Program (2020-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT